Breast-Conserving Treatment of Breast Cancer
An effective alternative to mastectomy for early stage disease regardless of age or hormone receptor status.
Randomized clinical trials have found similar survival rates for women who received breast-conserving surgery (lumpectomy) followed by radiation therapy and those who had a mastectomy for early-stage breast cancer. To determine if these results are the same in the general population (community practice), researchers from Duke University conducted a large, population-based retrospective review of outcomes of women who received lumpectomies plus radiation and those who had a mastectomy.
Information was obtained regarding all women diagnosed in the state of California with stage I or II breast cancer between 1990 and 2004, who were treated with either breast-conserving treatment or mastectomy and followed through December 2009. Analyses were stratified by age group (under and over age 50) and hormone receptor (HR) status. A total of 112,154 women fulfilled eligibility criteria. Women who received the breast-conserving treatment (lumpectomy and radiation) had improved overall survival and disease free survival than those who had mastectomies. The disease free survival was greater among women age over age 50 with HR-positive disease. The researchers concluded that these data provide confidence that breast-conserving treatment remains an effective alternative to mastectomy for early stage disease regardless of age or HR status.
The study report is available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.27795/abstract.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
